Cannabinoid Discrimination and Antagonism by CB(1) Neutral and Inverse Agonist Antagonists

Cannabinoid receptor 1 (CB(1)) inverse agonists (e.g., rimonabant) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications. Recent laboratory studies suggest that the effects of CB(1) neutral antagonists differ from those of such i...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Kangas, Brian D., Delatte, Marcus S., Vemuri, V. Kiran, Thakur, Ganesh A., Nikas, Spyridon P., Subramanian, Kumara V., Shukla, Vidyanand G., Makriyannis, Alexandros, Bergman, Jack
Formato: Artigo
Idioma:Inglês
Publicado: The American Society for Pharmacology and Experimental Therapeutics 2013
Assuntos:
Behavioral Pharmacology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3583508/
https://ncbi.nlm.nih.gov/pubmed/23287700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.112.201962
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares